Results 191 to 200 of about 373,386 (221)

Nutrition Education Services Described on National Cancer Institute (NCI)-Designated Cancer Center Websites

Journal of Cancer Education, 2017
For women diagnosed with breast cancer, healthy weight and enhanced nutrition may improve outcomes. The goal of this study is to examine the nutrition education services available on National Cancer Institute (NCI)-Designated Cancer Centers' websites.
Rani, Polak, Julia M, Reilly, Lauren E, Elson, Vanessa C, Gallegos-Kearin, Saurabha, Bhatnagar, Jeffery C, Schneider, Julie K, Silver   +6 more
openaire   +2 more sources

NCI mpact: National Cancer Institute molecular profiling-based assignment of cancer therapy.

Journal of Clinical Oncology, 2014
TPS2642 Background: There is growing interest in matching targeted agents to genetic aberrations found in tumors of patients in early phase trials.
Shivaani Kummar, Mickey Williams, Chih-Jian Lih, Alice P. Chen, Larry Rubinstein, Ramya Antony, Eric Polley, Yingdong Zhao, Barbara A. Conley, Richard Simon, James H. Doroshow   +10 more
openaire   +1 more source

Management of thymic epithelial tumors (TETs) at the National Cancer Institute (NCI).

Journal of Clinical Oncology, 2011
e17511 Background: TETs are very rare anterior mediastinal tumors. Methods: We performed a retrospective review of patients (pts.) with TETs presenting to the NCI for enrollment in ongoing clinical trials, standard-of-care therapy or a second opinion. Results: Seventy-three pts.
A. Rajan, R. J. Kelly, A. Lopez-Chavez, C. A. Carter, E. Szabo, B. Scepura, M. J. (. Manu, A. W. Berman, G. Giaccone   +8 more
openaire   +1 more source

Graphical representations of patient tolerability data: Recommendations from the National Cancer Institute (NCI) Cancer Moonshot Standardization Working Group.

Journal of Clinical Oncology, 2021
e18612 Background: Effective communication of treatment tolerability data is essential for clinical decision making and improved patient outcomes, yet standardized approaches to the analysis and visualization of tolerability data in cancer clinical trials are currently limited.
Gillian Gresham, Gina L. Mazza, Blake Langlais, Bellinda King-Kallimanis, Lauren J. Rogak   +4 more
openaire   +1 more source

A survey of cancer support groups provided by national cancer institute (NCI) clinical and comprehensive centers

Psycho-Oncology, 1993
AbstractThe 42 National Cancer Institute Clinical and Comprehensive Cancer Centers were surveyed about their group support programs. All responding centers (81%) offered group support programs, an average of 3.5 groups per center. There were an average of 6.0 members per group. About an equal number of groups were composed of patients or family members
Burton A. Presberg, James L. Levenson
openaire   +1 more source

Evolution of multidisciplinary care: Experience of the National Cancer Institute (NCI) Community Cancer Centers Program (NCCCP).

Journal of Clinical Oncology, 2012
67 Background: A key aim of the NCCCP is to develop and improve the quality of multidisciplinary care (MDC). An assessment tool with nine key elements relevant to MDC structure and operations was developed to assess MDC maturity and set goals for continued quality improvement at individual sites and across the network.
Eliot Lawrence Friedman, Paul Morris, Margaret Currens, Kathleen M. Castro, Steven B. Clauser, Irene Prabhu Das, Angela Carrigan, Silvana Rivero   +7 more
openaire   +1 more source

Criteria for charity care at National Cancer Institute (NCI) -designated cancer centers.

JCO Oncology Practice
262 Background: According to the American Cancer Society, nearly half (47%) of cancer patients and survivors incurred medical debts to pay for cancer care, although most (98%) had health care coverage (2024 Survivor Views Survey). The financial toxicity from high cost of cancer care is itself a
Lucas T. Go, Lewis T. Go, Jithma P. Abeykoon   +2 more
openaire   +1 more source

Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI)

Investigational New Drugs, 1996
Well-designed and carefully conducted pediatric phase 1 trials are critical to the process of evaluating new agents for potential benefit in children with cancer, and the National Cancer Institute (NCI) has for a number of years sponsored pediatric phase I trials.
M, Smith, P T, Ho
openaire   +2 more sources

Leading the way: The National Cancer Institute’s (NCI) single IRB for multi-site research.

Journal of Clinical Oncology, 2017
e18259 Background: NCI instituted a Central IRB (CIRB) with voluntary participation in 2001 for its late-phase trials and demonstrated that efficiency could be improved and costs reduced (Wagner et al JCO, 2010; 28). As a forerunner to the new NIH policy for single IRBs for all NIH multi-site trials (Hudson et al. JAMA Oct 4, 2010), NCI implemented a
Holly A. Massett, Jacqueline Goldberg, Sharon Hampp, Margaret M. Mooney, Brian Campbell, Suma Narasimhaswamy, Grace Mishkin, Ravi Rajaram, Laura Covington, Michael Montello, Andrea Denicoff, Martha Kruhm, Jeffrey S. Abrams   +12 more
openaire   +1 more source

Impact of National Cancer Institute (NCI)-mandated scientific review on protocol development and content.

Journal of Clinical Oncology, 2014
6586 Background: The National Cancer Institute (NCI) requirement that all clinical trials involving cancer patients at NCI-designated cancer centers undergo a scientific review in addition to Insti...
Ning Ning, Jingsheng Yan, Xian-Jin Xie, David E. Gerber   +3 more
openaire   +1 more source